NCT00072722已完成2 期
Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 4
研究概览
简要总结
Phase II randomized open-label, two-arm study of safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer (HRPC)
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Understand and voluntarily sign an informed consent form
- •Adult male subjects, age 18 or older at the time of signing the informed consent form
- •Able to adhere to the study visit schedule and other protocol requirements
- •Histologically confirmed adenocarcinoma of the prostate with radiographic evidence of metastases and PSA progression following hormonal therapy for metastatic disease. Subjects must have evidence of progression of disease as demonstrated by 2 consecutive rises in PSA (an absolute change of at least 1ng/ml) separated by at least 28 days.
- •Antiandrogen therapy must have been stopped at least 4 weeks (for flutamide) or 6 weeks (for bicalutamide or nilutamide) prior to entering study with evidence of a rising PSA (from baseline) measured x 2 at least 2 weeks apart Testicular androgen suppression must be maintained with either LHRH therapy of bilateral orchiectomy.
- •Must use barrier contraception (latex condom) when engaging in reproductive activity with women of child-bearing potential throughout the course of study treatment and for 4 weeks following the discontinuation of study treatment.
- •May have had only one prior regimen of chemotherapy for prostate cancer. The chemotherapy must have been stopped at least 4 weeks prior to study entry.
- •Disease-free of other malignancies for greater than 5 years with the exception of curatively treated basal cell, squamous cell carcinoma of the skin of Ta transitional cell carcinoma of the bladder.
- •ECOG performance status of 0 or
- •Serum creatinine greater than or equal to 2.0 mg%
- •Adequate hematologic functions: Granulocytes greater than or equal to 1800 mm3 and platelets greater than or equal to 100,000 mm
- •Adequate hepatocellular function: AST<2 x normal and bilirubin<1.5mg/dl
- •No active unresolved infection
排除标准
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study or confounds the ability to interpret data from the study.
- •Use of any other experimental drug or therapy within 28 days of baseline.
- •Any prior use of CC-4047 of Thalidomide
- •Tumors containing small cell or sarcomatoid elements
- •Symptomatic bone metastases.
- •Concurrent use of any other anti-cancer agents.
- •Known brain disease that is symptomatic, is currently being treated with corticosteroids, or has not been previously irradiated.
- •Non-PSA producing tumors
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
CC-4047 (Pomalidomide) for Graft vs. Host DiseaseGraft vs Host DiseaseNCT00770757Washington University School of Medicine13
Unknown
2 期
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine TumorExtrapancreatic Neuroendocrine TumorNCT03204032Chinese Academy of Medical Sciences60
Unknown
2 期
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine TumorPancreatic Neuroendocrine TumorNCT03204019Chinese Academy of Medical Sciences60
已完成
2 期
A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)Lymphocytic Leukemia, ChronicNCT01414205Genentech, Inc.80
已完成
2 期
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific AntibodyMalignant AscitesNCT06266091Wuhan YZY Biopharma Co., Ltd.115